Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DS-3939a |
Synonyms | |
Therapy Description |
DS-3939a is an antibody-drug conjugate (ADC) comprising an antibody targeting tumor-associated MUC1 (TA-MUC1) linked to a topoisomerase I inhibitor, which potentially induces cell cycle arrest and apoptosis of TA-MUC1-expressing tumor cells and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 6579)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DS-3939a | DS3939a|DS 3939a | DS-3939a is an antibody-drug conjugate (ADC) comprising an antibody targeting tumor-associated MUC1 (TA-MUC1) linked to a topoisomerase I inhibitor, which potentially induces cell cycle arrest and apoptosis of TA-MUC1-expressing tumor cells and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 6579)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05875168 | Phase Ib/II | DS-3939a | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | BEL | 1 |